Business Wire

THALES

23.5.2022 17:17:09 CEST | Business Wire | Press release

Share
Innovative IoT Modem Card From Thales Makes It Easier to Build a 5G World of Trust

Thales announces the new Cinterion® MV32 modem card that makes it quicker and easier for manufacturers to build and maintain resilient, high-performance 5G devices that will transform everyday life in the years ahead. Harnessing the full potential of 5G Mobile Broadband connectivity, the new modem card is designed to be at the heart of a wide array of demanding IoT (Internet of Things) use cases, such as securely connecting enterprises, remote patient care and intelligent monitoring of renewable energy generation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005024/en/

Effortlessly connecting 5G networks and next-gen IoT devices

The 5G roll-out will not only bring unprecedented mobile broadband speed to billions of people worldwide. It also offers an extraordinary leap in the sheer number of devices that cellular networks can support. Connectivity will be enabled for billions more machines. As a result, 5G is laying the foundations for vast new fleets of permanently connected IoT devices that enable a more sustainable and trustworthy future for us all.

Many of these new IoT devices will be highly compact. Thales’ space-saving 5G modem card therefore represents the ideal partner for the tiny embedded SIMs (eSIMs) that are another key building block for effortless connectivity. Next-generation IoT applications will demand the always-on, ultra-high speed connectivity and exceptional reliability that characterises the new Cinterion MV32 modem card:

  • Extensively leverages Thales’ broad expertise in providing successful 5G IoT solutions that manage connectivity plans in the field, enabling seamless, go-anywhere 5G.
  • Reliably delivers superior 5G cellular performance, thanks to industry’s most advanced and optimized radio frequency design, to enable the ultra-high speed and low latency.1

Protecting against a new wave of cyber-threats

For all its benefits, the distributed, virtualized, software-based design of many 5G networks also brings with it new vulnerabilities to cyber-attack. In response, the Cinterion MV32 5G modem card embodies Thales’ unrivalled expertise and experience in bringing robust security and protection to the 5G domain:

  • Leverages Thales’ security-by-design philosophy and core expertise in robust cyber-protection – enabling dynamic protection of devices in the field and over the entire lifecycle through secure remote updates.
  • Stringently and continuously penetration-tested by independent security experts.

“We were able to be a first-mover in 5G branch networking devices, in part because Thales provided a great globally-certified solution with support to a wide variety of frequency bands. They also provided responsive support to our engineers and have been a reliable supplier even when everything else is in shortage. We look forward to deploying Thales’ next-gen 5G SA MV32 into our devices in the coming year.” Keith Chau, general manager, Peplink

“For our customers, the latest generation MV32 5G modem card represents just the right product at the right time. Manufacturers worldwide must look at 5G to enable revolutionary new IoT solutions that will touch every aspect of our lives. Our new solution makes it a cinch to embed this ultra-fast connectivity. There is no trade-off between speed, latency, reliability and cyber-protection: the compact MV32 delivers them all.” Thierry Uguen, Director Product Management IoT at Thales

1 Further technical annotations :

  • The new Cinterion 5G data card leverages the industry-standard M.2 form factor for easy plug-and-play as well as the latest 3GPP Release 16 enhanced Mobile Broadband (eMBB) standard for peak performance.
  • It consistently supports the highest levels of data throughput without overheating as a result of its sophisticated thermal design.
  • Its radio frequency design also reduces complexity and increases reliability allowing the device to tap into the highest performance grade on the field, by leveraging the latest network deployments.

To learn more, join one of our virtual launch events on May 24 at 9:00 AM or 5:00 PM.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT
Thales Group
Digital Identity & Security and Thales MV32 modem card
@Thalesgroup

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye